We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bristol Myers Squibb (BMY) Suffers a Larger Drop Than the General Market: Key Insights
Read MoreHide Full Article
In the latest close session, Bristol Myers Squibb (BMY - Free Report) was down 2.4% at $55.26. This move lagged the S&P 500's daily loss of 0.06%. On the other hand, the Dow registered a loss of 0.17%, and the technology-centric Nasdaq decreased by 0.06%.
Prior to today's trading, shares of the biopharmaceutical company had gained 6.17% outpaced the Medical sector's loss of 0.79% and the S&P 500's gain of 1.99%.
Market participants will be closely following the financial results of Bristol Myers Squibb in its upcoming release. The company plans to announce its earnings on February 5, 2026. The company is expected to report EPS of $1.6, down 4.19% from the prior-year quarter. Alongside, our most recent consensus estimate is anticipating revenue of $12.28 billion, indicating a 0.49% downward movement from the same quarter last year.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $6.48 per share and revenue of $47.91 billion. These totals would mark changes of +463.48% and 0%, respectively, from last year.
It is also important to note the recent changes to analyst estimates for Bristol Myers Squibb. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, there's been a 0.38% rise in the Zacks Consensus EPS estimate. Bristol Myers Squibb is currently a Zacks Rank #3 (Hold).
From a valuation perspective, Bristol Myers Squibb is currently exchanging hands at a Forward P/E ratio of 9.38. For comparison, its industry has an average Forward P/E of 19.55, which means Bristol Myers Squibb is trading at a discount to the group.
It's also important to note that BMY currently trades at a PEG ratio of 9.38. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. BMY's industry had an average PEG ratio of 1.48 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 98, finds itself in the top 40% echelons of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Bristol Myers Squibb (BMY) Suffers a Larger Drop Than the General Market: Key Insights
In the latest close session, Bristol Myers Squibb (BMY - Free Report) was down 2.4% at $55.26. This move lagged the S&P 500's daily loss of 0.06%. On the other hand, the Dow registered a loss of 0.17%, and the technology-centric Nasdaq decreased by 0.06%.
Prior to today's trading, shares of the biopharmaceutical company had gained 6.17% outpaced the Medical sector's loss of 0.79% and the S&P 500's gain of 1.99%.
Market participants will be closely following the financial results of Bristol Myers Squibb in its upcoming release. The company plans to announce its earnings on February 5, 2026. The company is expected to report EPS of $1.6, down 4.19% from the prior-year quarter. Alongside, our most recent consensus estimate is anticipating revenue of $12.28 billion, indicating a 0.49% downward movement from the same quarter last year.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $6.48 per share and revenue of $47.91 billion. These totals would mark changes of +463.48% and 0%, respectively, from last year.
It is also important to note the recent changes to analyst estimates for Bristol Myers Squibb. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, there's been a 0.38% rise in the Zacks Consensus EPS estimate. Bristol Myers Squibb is currently a Zacks Rank #3 (Hold).
From a valuation perspective, Bristol Myers Squibb is currently exchanging hands at a Forward P/E ratio of 9.38. For comparison, its industry has an average Forward P/E of 19.55, which means Bristol Myers Squibb is trading at a discount to the group.
It's also important to note that BMY currently trades at a PEG ratio of 9.38. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. BMY's industry had an average PEG ratio of 1.48 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 98, finds itself in the top 40% echelons of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.